Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

FGFR

The fibroblast growth factor receptors (FGFR) are, as their name implies, receptors that bind to members of the fibroblast growth factor (FGF) family of proteins. Some of these receptors are involved in pathological conditions. For example, a point mutation in FGFR3 can lead to achondroplasia.

  • AZD4547
    T19481035270-39-3
    AZD4547, a new-type specific FGFR inhibitor, targets for FGFR1/2/3 (IC50: 0.2/2.5/1.8 nM in cell-free assays).
    • $33
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Erdafitinib
    T37261346242-81-6
    Erdafitinib (JNJ-42756493) is a quinoxaline derivative compound, acts on FGFR1/2/3/4.
    • $39
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Futibatinib
    T50441448169-71-8
    Futibatinib (FGFR-IN-1) is a novel, potent and highly selective FGFR inhibitor, used for antitumor treatment.
    • $53
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
  • Derazantinib
    TQ02281234356-69-4
    Derazantinib (ARQ-087) (ARQ-087) is an ATP competitive tyrosine kinase inhibitor. It exhibits potent activity against FGFR1/FGFR2/FGFR3 chondrocytes (IC50s: 4.5 nM/1.8 nM/4.5 nM).
    • $52
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
  • Lenvatinib
    T0520417716-92-8
    Lenvatinib (E7080) is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, and has oral activity. Lenvatinib has the strongest inhibitory activity on VEGFR2 and VEGFR3 (IC50=4/5.2 nM). Lenvatinib has strong anti-tumor activity.
    • $40
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Fisogatinib
    T34561707289-21-1
    Fisogatinib (BLU-554) is a potent inhibitor of fibroblast growth factor receptor 4 (FGFR4).
    • $51
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Ferulic Acid
    T22151135-24-6
    Ferulic Acid (Coniferic acid) is a highly abundant phenolic phytochemical and a type of organic compound found in the Ferula assafoetida L. or Ligusticum chuanxiong.It can be absorbed by the small intestine and excreted through the urine.
    • $30
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Pazopanib
    T0097L444731-52-6
    Pazopanib (GW786034), a small molecule inhibitor, inhibits multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits VEGFR-1, -2 and -3, c-kit and PDGF-R, which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.
    • $42
    In Stock
    Size
    QTY
  • Nintedanib
    T1777656247-17-5
    Nintedanib (Intedanib) is a triple vascular kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50=34/13/13 nM), FGFR1, FGFR2, and FGFR3 (IC50=69/37/108 nM), PDGFRα, and PDGFRβ (IC50=59/65 nM). Nintedanib has antitumor activity and inhibits tumor growth by inhibiting angiogenesis.
    • $38
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Formononetin
    T0724485-72-3
    Formononetin (Flavosil) is an O-methylated isoflavone and a phytoestrogen from the root of Astragalus membranaceus.
    • $45
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Amlexanox
    T163968302-57-8
    Amlexanox (AA673) is an anti-aphthous ulcer drug. Amlexanox inhibits the synthesis and release of inflammatory mediators, including leukotrienes and histamine, from mast cells, neutrophils, and mononuclear cells. Amlexanox also acts as a leukotriene D4 antagonist and a phosphodiesterase inhibitor. Amlexanox decreases the time ulcers take to heal as well as the pain associated with the ulcers.
    • $32
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • CP-547632
    T10870L252003-65-9In house
    CP-547632 is an orally available and potent, ATP-competitive dual inhibitor of VEGFR-2 and FGF kinase F with IC50s of 11 nM and 9 nM, respectively. CP-547632 is selective, with higher selectivity for VEGFR2 and bFGF than for EGFR, PDGFRβ and related tyrosine kinases (TKs). PDGFRβ and related tyrosine kinases (TKs) CP-547632 has antitumour activity.
    • $30
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • FGFR2-IN-1
    T613042677709-76-9
    FGFR2-IN-1 is an FGFR inhibitor that inhibits FGFR1, FGFR2, and FGFR3 with IC50s of 460, 140, and 2200 nM, respectively.FGFR2-IN-1 can be used for the study of cancers associated with FGFR2.CAS 번호13460-73-81-1
    • $56
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • SM27
    T248046266-54-2In house
    SM27 is a fibroblast growth factor 2 (FGF2) inhibitor with anti-angiogenic activity and can be used to study tumours.
    • $195
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • FIIN-4
    T273192093088-81-2In house
    FIIN-4 is a covalent inhibitor of FGFR and can be used in studies about metastatic breast cancer.
    • $329
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • FIIN-1
    T374261256152-35-8In house
    FIIN-1 (FGFR irreversible inhibitor-1) is an irreversible and selective FGFR inhibitor with Kd of 2.8, 6.9, 5.4, 120, 32 and 120 nM for FGFR1, FGFR2, FGFR3, FGFR4, Flt1, Flt14, respectively.FIIN-1 inhibited FGFR1, FGFR2, FGFR3, FGFR4, with IC50 of 9.2, 6.2, 11.9 and 189 nM. FIIN-1 inhibited FGFR1, FGFR2, FGFR3 and FGFR4, with IC50s of 9.2, 6.2, 11.9 and 189 nM, respectively.
    • $72
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • CP-547632 hydrochloride
    T10870252003-71-7In house
    CP-547632 hydrochloride is a well-tolerated and orally-bioavailable inhibitor of the VEGFR-2 and basic FGF kinases (IC50s: 11 nM and 9 nM) with antitumor efficacy.
    • $44
    5 days
    Size
    QTY
    TargetMol | Inhibitor Sale
  • TG 100572 Hydrochloride
    T13156L867331-64-4In house
    TG 100572 Hydrochloride is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively).
    • $399
    In Stock
    Size
    QTY
  • ZM323881 hydrochloride
    T1991193000-39-4In house
    ZM323881 hydrochloride (ZM 323881 HCl) is a potent and selective VEGFR2 inhibitor.
    • $66
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Danusertib
    T2094827318-97-8
    Danusertib (PHA-739358) is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may result in cell growth arrest and apoptosis in tumor cells in which Aurora kinases are overexpressed.
    • $54
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • TAK-632
    T18861228591-30-7
    TAK-632 is a potent pan-Raf inhibitor.
    • $35
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Ponatinib
    T2372943319-70-8
    Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively).
    • $50
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Infigratinib
    T1975872511-34-7
    Infigratinib (NVP-BGJ398) (BGJ398) is an orally bioavailable pan FGFR inhibitor (IC50: 0.9/1.4/1 nM for FGFR1/2/3), >40-fold selective for FGFR versus FGFR4 and VEGFR2.
    • $39
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • FGFR3-IN-7
    T824042833703-79-8
    FGFR3-IN-7 is a potent, selective inhibitor of FGFR 3, demonstrating an IC50 value of less than 350 nM , and is utilized in cancer research [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Sucralfate
    T133854182-58-0
    Sucralfate (Sucrose octasulfate–aluminum complex) is a cytoprotective agent, an oral gastrointestinal medication primarily indicated for the treatment of active duodenal ulcers.
    • $43
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • FGFR3-IN-6
    T824052833703-72-1
    FGFR3-IN-6 is a potent, selective inhibitor of FGFR 3, exhibiting an IC50 value of less than 350 nM , and is utilized in cancer research [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Fazpilodemab
    T783132517935-02-1
    Fazpilodemab (BFKB8488A) is a humanized agonistic bispecific antibody that targets fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. It is utilized in research pertaining to Type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Vofatamab
    T768771312305-12-6
    Vofatamab (B-701) is a fully human monoclonal antibody targeting FGFR3. Vofatamab has potential anticancer and antitumor activity and is often used in combination with other compounds to treat cancer.
    • $339
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Bemarituzumab
    T766731952272-74-0
    Bemarituzumab is a novel humanized IgG1 monoclonal antibody targeting FGFR2b. Bemarituzumab prevents FGFR2b from binding to FGF and activation. Potential applications of Bemarituzumab in cancer research.
    • $198
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Irpagratinib
    T798502230974-62-4
    Irpagratinib (ABSK011) is an orally active fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor with specificity for FGFR4, exhibiting an IC50 of less than 10 nM. It effectively inhibits FGFR4 auto-phosphorylation and disrupts subsequent signal transduction to downstream pathways. Demonstrating high exposure in pharmacokinetic studies in mice, rats, and dogs, Irpagratinib also displays antineoplastic activity in subcutaneous xenograft tumor models [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Aprutumab
    T766721634620-63-5
    Aprutumab (BAY 1179470) is a human FGFR2 monoclonal antibody with affinity to FGFR2 isoforms FGFR2-IIIB and FGFR2-IIIC. Aprutumab is commonly used to synthesize antibody-drug conjugates.
    • $572
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • LY2874455
    T23611254473-64-7
    LY2874455 has been used in trials studying the treatment of Advanced Cancer.
    • $58
    In Stock
    Size
    QTY
  • S6K2-IN-1
    T79871
    S6K2-IN-1 (Compound 2) is an inhibitor of S6K2 with an IC50 of 22 nM and also exhibits inhibitory activity against FGFR4 with an IC50 of 216 nM. This compound demonstrates acceptable stability in mouse liver microsomes [1].
    • Inquiry Price
    Size
    QTY
  • Resigratinib
    T798562750709-91-0
    Resigratinib (KIN-3248) is a FGFR tyrosine kinase inhibitor exhibiting antineoplastic activity [1].
    • Inquiry Price
    Size
    QTY
  • ODM-203
    T76111430723-35-5
    ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
    • $36
    In Stock
    Size
    QTY
  • H3B-6527
    T77381702259-66-2
    H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma, with antineoplastic activity.
    • $64
    In Stock
    Size
    QTY
  • PD-161570
    T23127192705-80-9
    PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC50 of 39.9 nM and a Ki of 42 nM. PD-161570 also inhibits the PDGFR, EGFR and c-Src tyrosine kinases with IC50 values of 310 nM, 240 nM, and 44 nM, respectively.
    • $98
    In Stock
    Size
    QTY
  • Lucitanib
    T151851058137-23-7
    Lucitanib (E-3810) is a novel VEGFR and FGFR inhibitor. It potently and selectively inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1 and FGFR2 (IC50s: 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively).
    • $40
    In Stock
    Size
    QTY
  • KHS101 hydrochloride
    T51701784282-12-7
    KHS101 is a TACC3 inhibitor and can selectively induce a neuronal differentiation phenotype.
    • $36
    In Stock
    Size
    QTY
  • S49076
    T32741265965-22-7
    S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.
    • $39
    In Stock
    Size
    QTY
  • Infigratinib phosphate
    T163641310746-10-1
    Infigratinib phosphate (BGJ-398 phosphate) is an effective inhibitor of the FGFR family (IC50: 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively).
    • $40
    In Stock
    Size
    QTY
  • PP58
    T13824212391-58-7
    PP58 is an inhibitor of PDGFR, FGFR and Src family.
    • $39
    In Stock
    Size
    QTY
  • EOC317
    T4318939805-30-8
    EOC317 (ACTB-1003) is an oral kinase inhibitor (IC50: 6/2/4 nM, for FGFR1/VEGFR2/Tie-2).
    • $93
    In Stock
    Size
    QTY
  • PHA-680632
    T6338398493-79-3
    PHA-680632 is potent inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 27 nM, 135 nM and 120 nM, respectively. It has 10- to 200-fold higher IC50 for FGFR1, FLT3, LCK, PLK1, STLK2, and VEGFR2/3.
    • $39
    In Stock
    Size
    QTY
  • Mal-amido-PEG2-C2-amido-Ph-C2-CO-AZD
    T164861037589-69-7
    Mal-amido-PEG2-C2-amido-Ph-C2-CO-AZD (PF-05231023) is a long-acting fibroblast growth factor 21 (FGF21) analog and is an FGF21-receptor agonist. It is also suitable for development as a potential treatment for T2DM.
    • $30
    In Stock
    Size
    QTY
  • FGFR2-IN-2
    T614732677709-81-6
    FGFR2-IN-2 is a specific FGFR2 inhibitor that inhibits FGFR1, FGFR2, and FGFR3, and can be used in the study of cancer and cardiovascular disease.
    • $1,360
    Backorder
    Size
    QTY
  • SU11274
    T6154658084-23-2
    SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.
    • $39
    In Stock
    Size
    QTY
  • Masitinib mesylate
    T85441048007-93-7
    Masitinib mesylate (AB-1010 mesylate) is a selective and orally bioavailable c-Kit inhibitor (IC50 of 200 nM,540/800 nM,510 nM for human recombinant c-Kit;PDGFRα/β;LynB,respectively).
    • $30
    In Stock
    Size
    QTY
  • Brivanib
    T6036649735-46-6
    Brivanib (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β. Phase 3.
    • $50
    In Stock
    Size
    QTY
  • FIIN-3
    T34661637735-84-2
    FIIN-3 is an irreversible inhibitor of FGFR.
    • $55
    In Stock
    Size
    QTY